I am a
Home I AM A Search Login

Papers of the Week

2022 Jan

Turk J Urol



Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients.


Mendes P A, Dias N, Simaes J, Dinis P, Cruz F, Pinto R
Turk J Urol. 2022 Jan; 48(1):82-87.
PMID: 35118993.


Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease, with consequent high morbidity. Increasing evidence suggests that bladder afferent hyperexcitability, through neurogenic bladder inflammation and urothelial dysfunction, plays a key role in the pathophysiology of BPS/IC. The rationale of using phosphodiesterase type 5 inhibitors (PDE5i) would be to decrease bladder afferent hyperactivity. Detrusor relaxation, improvement of microcirculation, and a decrease in adrenergic nociceptive overactivity would be other effects in bladder tissue. We aimed to evaluate the efficacy, tolerability, and safety of a daily low dose of 5mg tadalafil in refractory BPS/IC patients.